Though CAR T cells have been effective against certain blood cancers, they have not been for solid tumors. Now, a new form of ...

Scientists have discovered that T cell receptors activate through a hidden spring-like motion that had never been seen before. This breakthrough may help explain why immunotherapy works for some ...

Scientists at École Polytechnique Fédérale Lausanne (EPFL), and at UNIL-CHUV, University Hospital Lausanne (CHUV) and University of Lausanne (UNIL) have developed a computational method to create ...

In a new study published in GEN’s sister peer-review journal, GEN Biotechnology, titled, “Exploring Structure-Function Relationships in Engineered Receptor Performance Using Computational Structure ...

The first engineered cell therapy has come to the fight against solid tumors. Fox Chase Cancer Center has begun using Tecelra, an FDA-approved treatment for synovial sarcoma.

Among the most promising tools of cancer therapy, engineered immune cells known as chimeric antigen-receptor (CAR) T cells have already transformed the treatment of blood cancers. Yet, despite their ...

Imagine your immune cells could be modified to attack any kind of cancer. T cell receptor (TCR) therapy has the potential to one day become a universal cancer treatment. But there are risks.

One of the most exciting advances in cancer treatments in the past decade is the development of T cell immunotherapies, in which a patient's own immune system is trained to recognize and attack ...

New research combines two powerful imaging techniques to study the complete structure of a common aGPCR, including how its long and complex extracellular region interacts with the transmembrane region ...